Grace Therapeutics Posts $2.1M Q2 Loss, $21.3M Cash Through 2028

Grace Therapeutics, Inc. (Nasdaq: GRCE) reported a net loss of $2.1 million, or $0.11 per share, for the three months ended September 30, 2026, the company announced on November 12, 2026, alongside a business update on its lead drug candidate GTx-104. The loss widened by $1.2 million from a $0.9 million net loss, or $0.06 per share, in the same quarter a year earlier. Cash and cash equivalents stood at $21.3 million, up $4.3 million from $17.0 million at March 31, 2026.

Context — Why Grace Therapeutics' Cash Position Matters Now

The company's quarterly loss figure carries less weight than the balance sheet behind it. Grace Therapeutics is a late-stage biopharma with no product revenue, so its equity story rests on how long its cash lasts while regulators review its application. Management said the financing closed in August 2026 extends the expected cash runway through the end of calendar 2028.

The comparison the company itself provides is the prior-year quarter. In the three months ended September 30, 2025, Grace Therapeutics recorded a $1.4 million favorable change in the fair value of derivative warrant liabilities. That accounting gain reduced the reported loss that quarter. The applicable warrants have since expired, so no such benefit appeared in the 2026 period. The year-over-year loss widening is therefore partly a mechanical effect rather than a deterioration in spending.

What triggered the update is the U.S. Food and Drug Administration's Complete Response Letter issued on April 23, 2026, covering the company's New Drug Application for GTx-104. The FDA did not identify clinical safety or efficacy deficiencies and did not request additional clinical data, according to the company. The remaining items are chemistry, manufacturing and controls, plus non-clinical data.

Grace Therapeutics said it held a Type A meeting with the FDA and has received the meeting minutes. It is executing a previously disclosed plan to address the identified issues. Chief Executive Officer Prashant Kohli said the timing of the NDA resubmission will reflect whichever manufacturing site reaches readiness first.

Data — What the Numbers Show

The income statement moved in two directions. Research and development expenses rose to $0.9 million for the quarter from $0.6 million a year earlier, a $0.3 million increase the company attributed to higher third-party research activity tied to the dual-source manufacturing strategy and the required non-clinical studies. General and administrative expenses fell to $1.4 million from $2.0 million, a $0.6 million decline driven by lower legal fees, reduced pre-commercial planning for GTx-104, and lower salaries and benefits.

Metric	Q2 FY2027	Q2 FY2026	Change
Net loss	$2.1M	$0.9M	+$1.2M
Loss per share	$0.11	$0.06	+$0.05
R&D expense	$0.9M	$0.6M	+$0.3M
G&A expense	$1.4M	$2.0M	-$0.6M
Cash and equivalents	$21.3M	$17.0M	+$4.3M

The cash figure is a March 31, 2026 comparison rather than a prior-year quarter comparison. Cash used in operations for the six months ended September 30, 2026 was approximately $5.0 million. The August 2026 private placement of common stock to institutional and accredited investors raised $10 million gross, with net proceeds to the company of $9.2 million.

Share count expanded alongside the raise. Common shares issued and outstanding rose to 21,035,930 at September 30, 2026 from 16,024,026 at March 31, 2026. Weighted-average shares used in the per-share calculation were 20,116,776 for the quarter, versus 15,924,522 a year earlier. Total stockholders' equity was $55.5 million, down from $63.9 million at March 31, 2026.

The six-month picture differs sharply from the quarter because of a non-cash charge. Grace Therapeutics recorded a $13.5 million impairment of intangible assets in the six months ended September 30, 2026, with no comparable charge in the prior-year period. That pushed the six-month loss from operating activities to $18.2 million, versus $5.6 million a year earlier.

Analysis — What It Means for GRCE and Small-Cap Biotech

The central variable for Grace Therapeutics is not the quarterly loss but the FDA's view of its manufacturing supply chain. The company's current contract manufacturing organization received the CRL-related attention, responded to the FDA, and submitted a corrective action plan. Reinspection timing depends on that CMO's readiness and on FDA scheduling, the company said.

Grace Therapeutics is not waiting on a single site. It initiated technology transfer during the quarter to a second, U.S.-based CMO, starting with analytical method transfer. The NDA resubmission may be supported by either site, or both. That is a genuine hedge against single-site regulatory risk, but it also means the company is paying for parallel workstreams while carrying no revenue.

The counter-argument a bear would raise is dilution. The August raise added roughly five million shares, and the company has no approved product. If the resubmission slips beyond management's expectations, another financing becomes plausible. The company did not disclose the terms of any future funding.

GTx-104 has been granted Orphan Drug Designation by the FDA, which the company said provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval. Grace Therapeutics also cited 52 granted and pending patents covering the asset.

The commercial target is narrow but defined. aSAH accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital-treated patients per year, per the company. GTx-104 has been administered in over 200 patients and healthy volunteers, with the company reporting it was well tolerated and showed lower inter- and intra-subject pharmacokinetic variability than oral nimodipine capsules.

Positioning in a name like this tends to be event-driven. Specialists hold into regulatory milestones; generalist funds stay out until an approval or a clear resubmission date exists. The absence of a stated resubmission date keeps the stock in that holding pattern.

Outlook — What to Watch Next

The primary catalyst is NDA resubmission for GTx-104. The company tied the timing to whichever manufacturing pathway reaches readiness first, and it did not give a date. Progress on the second CMO's technology transfer, beginning with analytical method transfer, is the nearer-term operational marker.

A second catalyst is the reinspection of the current CMO. That depends on the CMO's own readiness and on FDA scheduling, both outside Grace Therapeutics' control. The company said it will report progress as key milestones are achieved.

On the financial side, watch the cash burn rate against the stated runway through the end of calendar 2028. Cash used in operations was approximately $5.0 million for the six months ended September 30, 2026. Any acceleration in R&D tied to the dual-source strategy would shorten that runway, and the company has not disclosed a financing plan beyond the August placement.

Frequently Asked Questions

What does the Grace Therapeutics Q2 2027 loss mean for retail investors?

It means the headline loss is not the whole story. The $2.1 million net loss was inflated by comparison to a prior-year quarter that included a $1.4 million favorable warrant fair-value change, a benefit that has now expired. Operating spending actually fell, with G&A down $0.6 million. The more relevant number for a pre-revenue biotech is the $21.3 million cash balance.

Why did Grace Therapeutics' research and development costs rise?

R&D rose $0.3 million to $0.9 million because the company is funding two things at once: the dual-source manufacturing strategy for GTx-104 and the non-clinical studies the FDA flagged in its Complete Response Letter. Both are tied to the NDA resubmission effort. The company said these were third-party research activities rather than internal headcount growth.